Joshua Fitch, Senior Editor

Lauren Flagg, DNP, APRN, CPNP-AC, discusses severe refractory status asthmaticus based on a session presented at the NAPNAP National Conference.

Of the 600,238 bivalent vaccine doses administered by all providers in the study period, 35,114 (5.9%) were done so by FRPP partners.

The pediatric approval to treat CABP is 1 of 3 indications approved by the FDA.

The single-arm study has an estimated enrollment of 93 participants, made up of females aged 2 to 8 years and males aged 2 to 9 years with CPP.

The phase 3 portion of the AMPLITUDE trial will include adolescents aged 10 to 17 years.

The planned phase 1/2 INSPIRE Duchenne trial (NCT06138639) is a first in-human, open-label, multicenter trial to evaluate tolerability and safety of SGT-003.

Chris Kyper, DNP, CPNP-AC/PC, breaks down characteristics of Heparin-induced thrombocytopenia, an uncommon adverse reaction to heparin.

A discussion of human trafficking awareness and what primary care providers can do to spot red flags and implement evidence-based knowledge.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

If approved, govorestat would be the first medication indicated for the treatment of galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize simple sugar galactose.

Tenofovir alafenamide was approved in 2022 to treat pediatric patients aged 12 years and older.

Insights between the pandemics, with a highlight on the dose-response relationship, "could be valuable in preparing health care systems for future pandemics," concluded the investigators.

Sally Humphrey, DNP, APRN, CPNP-PC, discusses current technology to treat youth with diabetes. Humphrey highlights continuous glucose monitoring systems (CGMs) and how they have evolved and improved.

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, provided a review and reminder of the CDC immunization recommendations and schedule during her session at the 45th National Association of Pediatric Nurse Practitioners (NAPNAP) National Conference on Pediatric Health Care in Denver, Colorado.

Ashley Gyura, DNP, CPNP-PC, provides updates presented at the 2024 NAPNAP National Conference, highlighting antiviral therapeutics for influenza, COVID-19, and herpes, among others.

TNX-2900 was previously granted Orphan Drug designation by the federal agency in 2022 for the treatment of PWS.

The initial dose of pemivibart is 4500 mg, which is administered as a single intravenous infusion. A repeat 4500 mg dose should be administered every 3 months if ongoing protection is needed, stated the FDA.

As of March 21, 2024, 64 measles cases have been reported to the CDC by 17 jurisdictions.

The investigators concluded that age-related risk differences "highlight the necessity for tailored strategies, improving understanding of and treatment development for RVIs."

The decision makes givinostat the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.

Cynthia Chew, DNP, CPNP-PC, IBCLC, assistant professor, University of Pittsburgh, breaks down her session, "The Why and How of Screening for Perinatal Mental Health Disorders in Pediatric Primary Care," presented at NAPNAP 2024.

An increase in measles cases, 58 confirmed to the CDC as of March 14, 2024, has prompted the agency to send a health advisory alert to health care providers.

Administration of the HIV-1 specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) to the indicated population can be done via 25 mg oral tablets or new 2.5 mg oral tablets, developed to help administration and weight-adjusted dosing for children.

What genetic red flags are associated with congenital heart disease? Jennifer Joiner, MSN, CPNP-AC/PC, joined Contemporary Pediatrics at the 45th NAPNAP National Conference to discuss the answer.

A discussion regarding current substance use trends for youth in the United States.

Traci Gonzales, MSN, APRN, CPNP-PC, explains her session presented at the 2024 NAPNAP National Conference, highlighting the ability to diagnose and manage uncommon causes of chronic respiratory symptoms.

Integrated data from a continuous glucose monitoring device (CGM) and an insulin pump to automate insulin delivery allow AID systems to manage patient blood sugar levels more "effectively," according to Sequel.

The decision makes atidarsagene autotemcel the first FDA-approved gene therapy for MLD, a rare genetic disease that affects the brain and nervous system.

Lara Smith, DNP, APRN, CPNP-AC/PC, provides case-based examples of endocrine emergencies in the pediatric ICU, based on her session presented at the 45th NAPNAP National Conference.

Psychopharmacologic agents used in the pediatric population from the perspective of their interactions with receptor targets in the brain and body.